Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Burkitt Lymphoma 20Neoplasm, Residual 9Leukemia 6Lymphoproliferative Disorders 4Lymphoma, Non-Hodgkin 4Lymphatic Diseases 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Lymphoid 3Recurrence 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoproliferative Disorders 2Blast Crisis 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Vincristine 2Methotrexate 2Mercaptopurine 2Hydrocortisone 2Cytarabine 2prednylidene 1pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Prednisolone 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Epirubicin 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Down Syndrome × blinatumomab × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡